Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf250 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Marla C Dubinsky und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Hauptthemen laut MEDLINE: Crohn Disease, Heterocyclic Compounds, 3-Ring, Adrenal Cortex Hormones, Janus Kinase Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U-EXCEL, U-EXCEED, U-ENDURE.
Abstract (Originalsprache)
Importance and Objective Upadacitinib, an oral, reversible Janus kinase inhibitor, is approved for the treatment of moderate-to-severe Crohn’s disease (CD). Limiting corticosteroid exposure is an important goal in treating CD. This posthoc analysis evaluated the corticosteroid-sparing effects of upadacitinib in patients with CD. Design and Setting This study included pooled data from two phase 3, multicenter, double-blind induction trials and one maintenance trial. Randomization was stratified by corticosteroid use at induction baseline, with a mandatory corticosteroid taper starting at induction week 4. Efficacy was evaluated by baseline corticosteroid use and by achieving corticosteroid-free outcomes through year 2 of maintenance therapy. Safety was also assessed. Results At baseline, 34.7% (234/674) and 35.7% (124/347) of upadacitinib 45 mg and placebo-treated patients were taking corticosteroids, respectively. At induction week 12 and maintenance week 52, higher rates of upadacitinib-treated patients were corticosteroid-free among all patients and among patients with baseline corticosteroid use compared with placebo; upadacitinib-treated patients achieved higher rates of corticosteroid-free outcomes, compared with placebo, including corticosteroid-free clinical remission (stool frequency/abdominal pain score [SF/APS]: 42.7% vs 16.1%; CD activity index [CDAI]: 41.2% vs 23.4%) and corticosteroid-free endoscopic response (37.0% vs 8.1%), with similar results observed among responders to upadacitinib induction therapy at maintenance week 52. Corticosteroid-free outcomes were sustained through year 2 of maintenance therapy. The safety profile was similar to the overall population, with no new safety risks identified. Conclusions and Relevance The results from pivotal studies demonstrated that upadacitinib effectively induced early and sustainable corticosteroid-free clinical remission with a manageable safety profile in patients with moderate-to-severe CD. Clinical trial identifiers U-EXCEL, U-EXCEED, and U-ENDURE ClinicalTrials.gov numbers, NCT03345849, NCT03345836, and NCT03345823.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
- Department of Gastroenterology and Hepatology, Clin. Univ. Saint Luc, UCLouvain, Brussels, Belgium.
- Clinic for Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland.
- Inflammatory Bowel Disease Unit, University of Calgary, Calgary, AB, Canada.
- Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
ORCID-Profile: Marla C Dubinsky, Pascal Juillerat, Remo Panaccione
Förderung
- U-EXCEL
- U-EXCEED
- U-ENDURE
Zitieren
APA
Dubinsky, M. C., D'Haens, G., Dewit, O., Juillerat, P., Panaccione, R., Fujii, T., Dubcenco, E., Lacerda, A. P., Anyanwu, S. I., Ford, S., Cunneen, C., Fish, I., Joshi, N., Garrison, A., & Loftus, E. V. (2025). Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf250
Vancouver
Dubinsky MC, D'Haens G, Dewit O, Juillerat P, Panaccione R, Fujii T, et al. Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf250
BibTeX
@article{Dubinsky2025,
author = {Dubinsky, Marla C and D'Haens, Geert and Dewit, Olivier and Juillerat, Pascal and Panaccione, Remo and Fujii, Toshimitsu and Dubcenco, Elena and Lacerda, Ana Paula and Anyanwu, Samuel I and Ford, Sharanya and Cunneen, Colla and Fish, Irina and Joshi, Namita and Garrison, Andrew and Loftus, Edward V},
title = {Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf250}
}
EUVIMED